# MCS in the Treatment of Lower Urinary Tract Symptoms

> **NCT01002417** · PHASE2,PHASE3 · COMPLETED · sponsor: **Health Ever Bio-Tech Co., Ltd.** · enrollment: 274 (actual)

## Conditions studied

- Lower Urinary Tract Symptoms
- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** MCS-2 15 mg/day
- **DRUG:** MCS-2 30 mg/day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01002417
- **Lead sponsor:** Health Ever Bio-Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002417, "MCS in the Treatment of Lower Urinary Tract Symptoms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01002417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*